X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs STERLING BIOTECH - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD STERLING BIOTECH STRIDES SHASUN LTD/
STERLING BIOTECH
 
P/E (TTM) x 13.3 -1.6 - View Chart
P/BV x 1.5 0.1 2,435.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES SHASUN LTD   STERLING BIOTECH
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
STERLING BIOTECH
Dec-13
STRIDES SHASUN LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,27511 12,140.0%   
Low Rs9183 27,000.0%   
Sales per share (Unadj.) Rs389.626.8 1,453.2%  
Earnings per share (Unadj.) Rs28.0-15.0 -187.0%  
Cash flow per share (Unadj.) Rs48.9-5.5 -895.1%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs303.154.9 552.3%  
Shares outstanding (eoy) m89.42267.87 33.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 1,085.5%   
Avg P/E ratio x39.2-0.5 -8,436.1%  
P/CF ratio (eoy) x22.4-1.3 -1,762.3%  
Price / Book Value ratio x3.60.1 2,856.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m98,0361,862 5,265.9%   
No. of employees `0005.81.4 428.4%   
Total wages/salary Rs m5,881547 1,075.6%   
Avg. sales/employee Rs Th6,005.95,303.3 113.2%   
Avg. wages/employee Rs Th1,014.0403.8 251.1%   
Avg. net profit/employee Rs Th431.2-2,959.0 -14.6%   
INCOME DATA
Net Sales Rs m34,8347,181 485.1%  
Other income Rs m1,68643 3,957.3%   
Total revenues Rs m36,5207,223 505.6%   
Gross profit Rs m6,428947 678.8%  
Depreciation Rs m1,8722,543 73.6%   
Interest Rs m2,2694,377 51.8%   
Profit before tax Rs m3,973-5,931 -67.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m470-1,924 -24.4%   
Profit after tax Rs m2,501-4,007 -62.4%  
Gross profit margin %18.513.2 139.9%  
Effective tax rate %11.832.4 36.5%   
Net profit margin %7.2-55.8 -12.9%  
BALANCE SHEET DATA
Current assets Rs m38,16514,335 266.2%   
Current liabilities Rs m30,40249,809 61.0%   
Net working cap to sales %22.3-494.0 -4.5%  
Current ratio x1.30.3 436.2%  
Inventory Days Days77403 19.2%  
Debtors Days Days104171 61.2%  
Net fixed assets Rs m37,63955,432 67.9%   
Share capital Rs m894268 333.8%   
"Free" reserves Rs m26,21013,935 188.1%   
Net worth Rs m27,10514,701 184.4%   
Long term debt Rs m16,3779,478 172.8%   
Total assets Rs m81,16873,988 109.7%  
Interest coverage x2.8-0.4 -774.9%   
Debt to equity ratio x0.60.6 93.7%  
Sales to assets ratio x0.40.1 442.2%   
Return on assets %5.90.5 1,173.3%  
Return on equity %9.2-27.3 -33.9%  
Return on capital %12.1-6.4 -187.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m13,4651,860 724.0%   
Fx outflow Rs m4,07625 16,374.8%   
Net fx Rs m9,3891,835 511.7%   
CASH FLOW
From Operations Rs m2,8811,719 167.6%  
From Investments Rs m-7,051-3,148 224.0%  
From Financial Activity Rs m3,3821,426 237.2%  
Net Cashflow Rs m-788-3 23,163.5%  

Share Holding

Indian Promoters % 27.7 33.9 81.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.0 -  
FIIs % 8.6 9.9 86.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 25.9 39.3 65.9%  
Shareholders   56,241 21,482 261.8%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 21, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - IPCA LABS COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS